Showing results (81-90 of 210) with videos related to

Sort By:
Pageof 21
Frontiers in Immunology|July 5, 2022
Identification of New Antibodies Targeting Malignant Plasma Cells for Immunotherapy by Next-Generation Sequencing-Assisted Phage DisplaySteffen Krohn, Ammelie Svea Boje, Carina Lynn Gehlert, et al.
Cancer|September 12, 2018
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trialMeletios A Dimopoulos, Sagar Lonial, Keith A Betts, et al.
Haematologica|September 25, 2025
Hepatitis E virus infections in people with multiple myeloma: an emerging challenge in the era of immunotherapeutic approachesMaximilian Al-Bazaz, Sven Pischke, Winfried Alsdorf, et al.
Leukemia & Lymphoma|June 2, 2020
Autologous stem cell transplantation in multiple myeloma patients: utilization patterns and hospital effectsLina Jansen, Maximilian Merz, Monika Engelhardt, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 10, 2023
Pomalidomide, Bortezomib, and Dexamethasone in Lenalidomide-Pretreated Multiple Myeloma: A Subanalysis of OPTIMISMM by Frailty and Bortezomib Dose AdjustmentAlbert Oriol, Meletios Dimopoulos, Fredrik Schjesvold, et al.
Journal of Hematology & Oncology|June 28, 2019
Prospective target assessment and multimodal prediction of survival for personalized and risk-adapted treatment strategies in multiple myeloma in the GMMG-MM5 multicenter trialDirk Hose, Susanne Beck, Hans Salwender, et al.
British Journal of Haematology|November 19, 2014
Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasoneGareth Morgan, Antonio Palumbo, Sujith Dhanasiri, et al.
The Lancet. Haematology|March 16, 2019
High cutoff versus high-flux haemodialysis for myeloma cast nephropathy in patients receiving bortezomib-based chemotherapy (EuLITE): a phase 2 randomised controlled trialColin A Hutchison, Paul Cockwell, Veronica Moroz, et al.
Hemasphere|September 4, 2023
Measurable Residual Disease Testing in Multiple Myeloma Routine Clinical Practice: A Modified Delphi StudyKarthik Ramasamy, Hervé Avet-Loiseau, Cecilie Hveding Blimark, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 8, 2015
Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III TrialKatja Weisel, Meletios Dimopoulos, Kevin W Song, et al.
Pageof 21